Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (41-50 of 162) with videos related to

Pageof 17
Sort By:
Frontiers in Molecular Biosciences|June 6, 2022
Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling MelanomaZarwa Yaseen, Tuba N Gide, Jordan W Conway, et al.
Journal of the American Academy of Dermatology|November 5, 2019
The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort studyNorbertus A Ipenburg, Serigne N Lo, Ricardo E Vilain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanomaJames S Wilmott, Georgina V Long, Julie R Howle, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|June 19, 2015
Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic ImplicationsEiji Kiyohara, Nicholas Donovan, Ling Takeshima, et al.
Pigment Cell & Melanoma Research|April 6, 2013
Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progressionGeorgina V Long, James S Wilmott, Lauren E Haydu, et al.
Pigment Cell & Melanoma Research|December 27, 2016
Mutation load in melanoma is affected by MC1R genotypePeter A Johansson, Antonia L Pritchard, Ann-Marie Patch, et al.
Molecular Cancer Therapeutics|September 11, 2012
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicineJames S Wilmott, Varsha Tembe, Julie R Howle, et al.
British Journal of Cancer|August 18, 2018
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosisChristoph Krisp, Robert Parker, Dana Pascovici, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentJames S Wilmott, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III MelanomaJason Madore, Dario Strbenac, Ricardo Vilain, et al.
Pageof 17

Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
Frontiers in Molecular Biosciences|June 6, 2022
Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling MelanomaZarwa Yaseen, Tuba N Gide, Jordan W Conway, et al.
Journal of the American Academy of Dermatology|November 5, 2019
The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort studyNorbertus A Ipenburg, Serigne N Lo, Ricardo E Vilain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanomaJames S Wilmott, Georgina V Long, Julie R Howle, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|June 19, 2015
Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic ImplicationsEiji Kiyohara, Nicholas Donovan, Ling Takeshima, et al.
Pigment Cell & Melanoma Research|April 6, 2013
Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progressionGeorgina V Long, James S Wilmott, Lauren E Haydu, et al.
Pigment Cell & Melanoma Research|December 27, 2016
Mutation load in melanoma is affected by MC1R genotypePeter A Johansson, Antonia L Pritchard, Ann-Marie Patch, et al.
Molecular Cancer Therapeutics|September 11, 2012
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicineJames S Wilmott, Varsha Tembe, Julie R Howle, et al.
British Journal of Cancer|August 18, 2018
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosisChristoph Krisp, Robert Parker, Dana Pascovici, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentJames S Wilmott, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III MelanomaJason Madore, Dario Strbenac, Ricardo Vilain, et al.
Pageof 17